93 results about "Influenza (flu)" patented technology

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention discloses a preparation method of influenza D virus-like particles, and belongs to the field of veterinary biological products. Influenza D virus (IDV) is one of important pathogens of bovine respiratory disease syndrome (BRDC), the disease causes a hundreds of billions of dollars economic loss to the global cattle raising industry every year, however, commercialized vaccines for influenza D do not exist in the market at present. The preparation method comprises the following steps: target gene amplification, construction of recombinant shuttle plasmids, construction of recombinant baculoviruses, rescue of recombinant baculoviruses, and preparation and purification of virus-like particles. The D-type influenza virus-like particles (IDV VLPs) are obtained through the steps. After mice are immunized, the IDV VLPs are found to have high immunogenicity and can be used as a candidate vaccine for preventing the D-type influenza.

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The collapsible saddle sleeper allows a person (e.g., adults or children) to collapse and transport the sleeper to any desired location to allow sleep in an angled position on their stomach (e.g., upper torso) and head in a straddle, sitting-like position, which helps reduce a variety of symptoms that are tied to specific medical conditions. In one example, the angled position may help a person to reduce and / or eliminate congestion and / or coughing while attempting to sleep when it's due to a common cold, flu or disease.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

The application discloses a recombinant nanobody against swine influenza virus of H1N1 subtype, and a preparation method and application thereof, and belongs to the field of biological medicines. A VHH sequence of the nanobody against swine influenza virus of H1N1 subtype is screened from a nanobody bacterial library of an immunized llama, the VHH sequence is directionally cloned into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, and the recombinant eukaryotic expression plasmid is transformed into a Pichia pastoris expression system to screen an expression engineering strain, and the recombinant nanobody is obtained after induction culture of the expression engineering strain. It is proved by in-vitro and in-vivo experiments that the recombinant nanobody developed in the application can neutralize CA / 04 and has a remarkable therapeutic effect. Therefore, the neutralizing nanobody provided in the application has considerable potential in treating CA / 04. The findings will provide experimental data for developing nanobody preparations against swine influenza virus of H1 subtype and provide a new strategy for preventing and controlling swine influenza.

The invention relates to a quinoline triazole compound and application thereof. The quinoline triazole compound has the structural characteristics as shown in formula I, and can effectively treat diseases caused by respiratory viruses such as influenza.

The invention uses ex vivo human airway cultures to assess the transmissibility and replication ability of influenza and coronavirus strains. By comparing the pandemic influenza A H1N1 and the highly pathogenic influenza A H5N1 as reference virus strains, the spreading risks of various viruses are evaluated and classified. In addition, an in vitro model is used to assess the degree of alveolar fluid clearance (AFC) impairment caused by the virus as an indicator of the severity of the disease. The research reveals the relevance among the virus replication ability, human transmission, AFC damage degree and clinical disease severity of different influenza and coronavirus strains in bronchus.

The invention relates to an application of a composition of seven probiotics in preparation of an anti-influenza virus probiotic agent. The bacterial strains in the probiotic composition comprise a combination of a streptococcus thermophilus CT-02 bacterial strain, a bifidobacterium animalis subsp. Lactis C-2 bacterial strain, a bifidobacterium longum subsp. Infantis C-3 bacterial strain, a lactobacillus delbrueckii subsp. Bulgaricus CB-01 bacterial strain, a lactobacillus acidophilus CL-01 bacterial strain, a lactobacillus paracasei CL-02 bacterial strain and a lactobacillus rhamnosus CL-03 bacterial strain. New application of the probiotic composition is developed, a research basis is provided for wide application of the probiotic composition, meanwhile, a brand-new strategy for preventing, relieving or treating influenza is also developed, it is found that the probiotic composition has a very remarkable effect in the aspect of relieving related symptoms caused by the influenza, and the probiotic composition has a good application prospect. Specifically, related symptoms such as respiratory system infection, body temperature imbalance, weight loss and vision weakening caused by influenza virus infection are obviously improved.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

Presented are assay modules for performing multiplex assays that detect many influenza virus-related nucleic acids simultaneously, including those from known influenza viruses and influenza virus subtypes as well as previously unknown, emerging influenza viruses and influenza subtypes, as well as other viruses and bacteria known to cause respiratory symptoms in humans and other animals. Neither sample preparation methods nor the assays necessarily require amplification of the sample nucleic acids yet the assays retain sensitivity, allow for multiplexing, and provide low cost, minimum automated workflow and results in less than thirty minutes.

The invention relates to an anti-influenza compound as well as a preparation method and application thereof, and the anti-influenza compound has a structure as shown in formula (I): (I) wherein X1 is CR3 or N; x2 is CR4 or N; z is CR5 or N; y1 is CR6 or N; y2 is CR7 or N; y3 is CR8 or N; w is-NH-or-N = CH-; in the formula, R1 is-R < 9 >-COO < 10 >,-(CR < 122 >) < n >-R < 11 >-(CR < 122 >) < n >-O-H,-(CR < 122 >) < m >-O-H,-(CR < 122 >) < h >-COO < 10 > or-R < 11 >-CONR < 13 >-R < 14 >. The compound provided by the invention has strong inhibitory activity on influenza virus, and is subjected to in-vivo antiviral activity test, action mechanism analysis and pharmacokinetic characteristic evaluation at the same time.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

1. Name of the Design Product: Graphical User Interface for Sales Data Statistics of Electronic Devices. 2. Use of the Design Product: An electronic device. 3. Design Key Points of the Design Product: Lies in the graphical user interface. 4. Picture or Photograph that Best Illustrates the Design Key Points: Front View. 5. Human-Computer Interaction Method of the Graphical User Interface: The front view shows the statistical data of varicella in a certain province. Clicking on the words "herpes zoster" or "influenza" at the top of the front view can switch to showing the statistical data of herpes zoster or influenza in a certain province; clicking on different prefecture-level cities in the national sales map of the front view jumps to the interface change state diagram, and the interface change state diagram shows the statistical data of each district and county under the jurisdiction of the corresponding prefecture-level city in the province in the national sales map.

The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.

The present application relates to the field of biochemistry, and discloses a multiple primer set and a kit for detecting pathogens of acute infection of the lower respiratory tract, including primer pairs for detecting Mycoplasma pneumoniae, primer pairs for detecting Chlamydia pneumoniae, primer pairs for detecting Staphylococcus aureus, primer pairs for detecting Haemophilus influenzae, primer pairs for detecting Streptococcus pneumoniae, and primer pairs for detecting Klebsiella pneumoniae. The multiple primer set for detecting pathogens of acute infection of the lower respiratory tract of the present application can realize simultaneous amplification and detection of 6 targets, and is suitable for screening of clinical cases of acute lower respiratory tract infection.

The invention discloses a recombinant nano antibody for resisting H1N1 subtype A swine influenza virus as well as a preparation method and application thereof, and belongs to the field of biological medicines. The preparation method comprises the following steps: screening a VHH sequence for resisting an A H1N1 subtype swine influenza virus from a nano antibody bacterial library of an immune alpaca, directionally cloning the VHH sequence into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, transforming the recombinant eukaryotic expression plasmid into a pichia pastoris expression system to screen and express an engineering strain, and carrying out induced culture on the engineering strain to obtain the recombinant nano antibody. In-vitro and in-vivo experiments prove that the recombinant nano antibody developed by the invention can neutralize CA / 04 and shows a remarkable treatment effect. Therefore, the neutralizing nano antibody provided by the invention has great potential in the aspect of treatment of CA / 04. The discovery provides test data for research and development of anti-H1 subtype swine influenza virus nano antibody preparations, and provides a new strategy for prevention and control of swine influenza.

To provide a prophylactic and therapeutic agent for viral respiratory infectious diseases comprising a new component.SOLUTION: The features of the present invention for solving the above problems are as follows. 1. A prophylactic or therapeutic agent for viral respiratory infection, comprising glucosylceramide and / or glucosylceramide as an active ingredient. (2) A prophylactic or therapeutic agent for viral respiratory infections, which comprises β - sitosterol glycoside as an active ingredient. (3) The prophylactic and therapeutic agent for viral respiratory infection according to (1) or (2) above, wherein the viral respiratory infection is influenza.SELECTED DRAWING: None

The present invention discloses the application of siRNA targeting the mGluR2 gene, monoclonal antibodies against the extracellular domain of the protein encoded by the mGluR2 gene, truncated peptides containing the extracellular domain of the protein encoded by the mGluR2 gene, or recombinant vectors containing the gRNA gene sequence targeting the mGluR2 gene and the CAS9 protein gene sequence in the preparation of preparations for inhibiting influenza virus, swine acute diarrhea syndrome coronavirus, porcine epidemic diarrhea virus, Japanese encephalitis virus, and porcine reproductive and respiratory syndrome virus. The present invention also discloses the application of a genetic engineering operation method for knocking out the mGluR2 gene in the preparation of a new mouse strain with enhanced influenza resistance. The aforementioned applications have prospects for promotion.

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

The invention discloses application of siRNA (small interfering Ribonucleic Acid) of a targeted mGluR2 gene, a monoclonal antibody for resisting an extracellular domain of a protein coded by the mGluR2 gene, a truncated peptide containing the extracellular domain of the protein coded by the mGluR2 gene or a recombinant vector containing a gRNA (guide Ribonucleic Acid) gene sequence and a CAS9 protein gene sequence of the targeted mGluR2 gene in preparation of a medicine for inhibiting influenza virus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute The invention also relates to application of the compound in preparations for treating porcine epidemic diarrhea virus, Japanese encephalitis virus and porcine reproductive and respiratory syndrome virus. The invention also discloses an application of the gene engineering operation method for knocking out the mGluR2 gene in preparation of a new mouse strain for improving influenza resistance. The application has a popularization prospect.

The invention provides a combined medicine composition for treating brain glioma and application. The medicine composition comprises a copper ion carrier and a targeted NEU1 anti-influenza medicine. According to the combined medicine composition, an effective medicine combination strategy is provided for treatment of the brain glioma, and the combined medicine composition comprises a copper ion carrier, namely the illicit and an anti-influenza medicine, namely the oseltamivir. According to the invention, the condition that the combination of the ilismos and the oseltamivir has a synergistic effect on the treatment of the brain glioma is found for the first time.

The application relates to application of dihydroergotamine mesylate in preparation of anti-influenza virus drugs and belongs to the technical field of medicines. The application provides application of dihydroergotamine mesylate in preparation of anti-influenza virus drugs. The dihydroergotamine mesylate can play a role in an early replication stage after influenza virus enters a host cell, can inhibit synthesis of influenza virus nucleic acid, can significantly improve lung symptoms caused by influenza A, reduces virus titer in lung tissues, has good cell safety, biological safety and effectiveness, and has a good anti-virus application prospect.

COVID-19 and many other infectious diseases like Flu can spread through by touch. Tennis player exchange the same balls multiple times during the practice or game. For student's safety schools and colleges currently sanitize the balls manually which is a tedious and time taking job. This invention sanitizes the bunch of tennis balls in one go with the push of a buttons and a Knob which control the speed of motor vibration.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention discloses an application of vocerotropine in preparation of a preparation which is independently used or used in combination with other preparations to prevent and treat influenza, slow down influenza or inhibit influenza virus proliferation. The vocerotropine and the composition containing the vocerotropine are good in safety, can well inhibit influenza virus proliferation, and have application prospects for treating influenza.

The invention relates to the field of biological medicine, and particularly discloses an RSV-influenza combined vaccine and application thereof. The RSV-influenza combined vaccine comprises a respiratory syncytial virus mRNA vaccine and an influenza vaccine, the respiratory syncytial virus mRNA vaccine also comprises lipid nanoparticles, and the mRNA is loaded in the lipid nanoparticles. The RSV-influenza combined vaccine is used for preventing infection of various respiratory viruses (RSV virus and influenza virus), and the LNP adjuvant of the RSV mRNA vaccine can greatly increase the immune response of the influenza vaccine and enhance the protection efficiency of the influenza vaccine in immunocompromised people.

The present disclosure provides AAV-delivered antibody compositions and kits for treating and / or preventing infectious diseases (for example, Human Immunodeficiency Virus (HIV)) and methods of use thereof. In some embodiments, it includes treating or preventing a human immunodeficiency virus (HIV), a hepatitis B virus (HBV), an influenza virus, or a respiratory syncytia) virus (RSV) infection in a subject, the method comprising administering a therapeutic regimen comprising rapamycin, or variants thereof, and a viral vector encoding a broadly neutralizing antibody (including, but not limited to a HIV broadly neutralizing antibody, a HBV broadly neutralizing antibody, an influenza broadly neutralizing antibody, or a RSV broadly neutralizing antibody).